GlassScriptPhysician profile
Barbara Caldwell
NPI 1003898032
$1,697.03
in general payments reported to CMS, 2019-2025
32 companies · $21.73 in 2025
The $21.73 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $228 · 2023: $765 · 2024: $73.89 · 2025: $21.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $452.28 | 2021-2023 | Tagrisso, Enhertu |
| Incyte Corporation | $170.23 | 2021-2023 | Jakafi |
| Celgene Corporation | $123.19 | 2022-2024 | Reblozyl, Opdualag |
| Exelixis INC. | $75.70 | 2022-2023 | Cabometyx |
| Beigene USA, INC. | $62.67 | 2023 | Brukinsa |
| Eisai INC. | $54.89 | 2021-2023 | |
| Immunogen, INC. | $52.50 | 2023 | Elahere |
| Janssen Biotech, INC. | $51.12 | 2022-2023 | Imbruvica, Darzalex |
| Boston Scientific Corporation | $41.55 | 2023 | |
| Servier Pharmaceuticals LLC | $35.22 | 2023 | |
| Seagen INC. | $34.86 | 2022-2023 | Padcev |
| Stryker Corporation | $34.37 | 2024 | 1788 |
| Merck Sharp & Dohme LLC | $33.95 | 2022 | |
| Sumitomo Pharma America, INC. | $33.23 | 2023 | Orgovyx |
| Karyopharm Therapeutics INC. | $33.11 | 2023 | Xpovio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.98 | 2023 | Kyprolis, Lumakras |
| Novartis Pharmaceuticals Corporation | $31.35 | 2022-2023 | |
| Astellas Pharma US INC | $30.40 | 2023 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $29.79 | 2023 | Adynovate |
| Davol INC. | $28.93 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $28.92 | 2023 | Onivyde, Somatuline Depot |
| Rigel Pharmaceuticals, INC. | $26.33 | 2021 | |
| Daiichi Sankyo INC. | $24.72 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.95 | 2022 | |
| Glaxosmithkline, LLC. | $21.73 | 2025 | Jemperli |
| Stemline Therapeutics INC. | $21.36 | 2023 | Orserdu |
| Myovant Sciences INC. | $20.83 | 2022 | |
| Cti Biopharma Corp. | $20.21 | 2023 | Vonjo |
| Gilead Sciences, INC. | $18.87 | 2022 | |
| Pfizer INC. | $17.80 | 2023 | |
| Genentech USA, INC. | $17.20 | 2023 | Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $13.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.